Medical Cannabis Commission; process for selecting integrated facility licenses revised, appeals process of commission determinations revised, number of integrated facility licenses to be issued increased
SB72 revises Alabama’s medical cannabis licensing framework, focusing on integrated facility licenses issued by the Alabama Medical Cannabis Commission. The bill would remove the requirement for a post-denial investigatory hearing, make commission licensing decisions final and conclusive in state courts, and make certain court orders that would block licensing immediately appealable to the Alabama Supreme Court. It also changes the licensing process by requiring the commission to hire an outside consultant to evaluate and select applicants from the pool that had submitted completed integrated facility applications by December 31, 2022, with the consultant’s selection treated as the commission’s final determination for legal purposes.
The bill also expands the number of integrated facility licenses from five to seven. Integrated facility licensees would continue to be authorized to cultivate, process, transport, and dispense medical cannabis, and the bill preserves the existing operational and financial requirements tied to those licenses, including bonding, liquid asset, and operational-capacity standards. The consultant-based selection process would be completed on a set timeline in late 2025 and early 2026, after which the commission would be required to issue licenses to the selected applicants.
SB72 would amend Sections 20-2A-56, 20-2A-57, 20-2A-67, and 20-2A-68 of the Code of Alabama 1975 and add new Section 20-2B-67.1. Its practical effect would be to narrow judicial and administrative review of medical cannabis licensing decisions, accelerate finality of those decisions, and shift the initial selection of integrated facility licensees to a consultant rather than the commission directly. It would also increase the number of integrated facility licenses available, affecting applicants, existing license holders, the Alabama Medical Cannabis Commission, and courts reviewing licensing disputes.
The available context suggests the bill was aimed at resolving or streamlining a contentious licensing process by imposing a more rigid selection mechanism and limiting litigation over commission decisions. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate tone or member positions in the supplied materials. The bill’s introduction and referral to the Agriculture, Conservation, and Forestry committee indicate it was actively considered, but its current status as indefinitely postponed suggests it did not advance to enactment.
The main points of contention appear to be the bill’s restriction of judicial remedies, the elimination of the post-denial investigatory hearing, and the use of an outside consultant to make binding license selections from the 2022 applicant pool. These provisions would likely be controversial for applicants who were denied licenses or who sought broader administrative or court review, while supporters would likely view them as a way to bring finality and reduce delays in the medical cannabis licensing process. The increase from five to seven integrated facility licenses may also have been debated, as it affects the distribution of a limited number of valuable licenses.